Published in:
Open Access
01-12-2012 | Research article
Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury
Authors:
Marc Schoeler, Philip D Loetscher, Rolf Rossaint, Astrid V Fahlenkamp, Georg Eberhardt, Steffen Rex, Joachim Weis, Mark Coburn
Published in:
BMC Neurology
|
Issue 1/2012
Login to get access
Abstract
Background
The α2-adrenoreceptor agonist dexmedetomidine is known to provide neuroprotection under ischemic conditions. In this study we investigated whether dexmedetomidine has a protective effect in an in vitro model for traumatic brain injury.
Methods
Organotypic hippocampal slice cultures were subjected to a focal mechanical trauma and then exposed to varying concentrations of dexmedetomidine. After 72 h cell injury was assessed using propidium iodide. In addition, the effects of delayed dexmedetomidine application, of hypothermia and canonical signalling pathway inhibitors were examined.
Results
Dexmedetomidine showed a protective effect on traumatically injured hippocampal cells with a maximum effect at a dosage of 1 μM. This effect was partially reversed by the simultaneous administration of the ERK inhibitor PD98059.
Conclusion
In this TBI model dexmedetomidine had a significant neuroprotective effect. Our results indicate that activation of ERK might be involved in mediating this effect.